- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Behavior Rating Inventory of Executive Function.
Displaying page 1 of 1.
EudraCT Number: 2013-003731-29 | Sponsor Protocol Number: WMTvsritalin | Start Date*: Information not available in EudraCT |
Sponsor Name:SSE, Nevroklinikken, Oslo Universitetssykehus | ||
Full Title: Could working memory training with computer games be an alternative to stimulant medication for children and adolescents with attention deficits and epilepsy? | ||
Medical condition: Epilepsy and comorbid ADHD/ADD | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001263-23 | Sponsor Protocol Number: BP27832 | Start Date*: 2014-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) | |||||||||||||
Medical condition: Down Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001256-42 | Sponsor Protocol Number: YKP509C003 | Start Date*: 2023-03-08 | |||||||||||
Sponsor Name:SK Life Science, Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in C... | |||||||||||||
Medical condition: Lennox-Gastaut syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001916-37 | Sponsor Protocol Number: MATRICS_WP6-1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:RADBOUD UNIVERSITY MEDICAL CENTER | |||||||||||||
Full Title: The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD) | |||||||||||||
Medical condition: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004496-12 | Sponsor Protocol Number: 1042-PCDH19-3002 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Marinus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | |||||||||||||
Medical condition: protocadherin 19 (PCDH19)-related epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) NL (Prematurely Ended) PL (Completed) HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002171-94 | Sponsor Protocol Number: Newrofeed | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Mensia Technologies SA | |||||||||||||
Full Title: Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder... | |||||||||||||
Medical condition: Attention Deficit-Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002804-14 | Sponsor Protocol Number: ZX008-1503 | Start Date*: 2016-11-08 | |||||||||||
Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc | |||||||||||||
Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome | |||||||||||||
Medical condition: Seizures associated with Dravet syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) DK (Completed) ES (Ongoing) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003405-26 | Sponsor Protocol Number: NF1-EXCEL | Start Date*: 2014-09-03 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | |||||||||||||
Medical condition: Neurofibromatosis type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) DK (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
